 SAN FRANCISCO--BUSINESS WIRE--Better Therapeutics, Inc. NASDAQ: BTTX, a prescription digital therapeutics PDT company developing nutritional cognitive behavioral therapy nCBT to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen 